This company has been marked as potentially delisted and may not be actively trading. NYSE:PTHN Patheon N.V. Ordinary shares, p (PTHN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Patheon N.V. Ordinary shares, p Stock (NYSE:PTHN) 30 days 90 days 365 days Advanced Chart Get PTHN alerts:Sign Up Key Stats Today's Range$34.98▼$34.9850-Day Range N/A52-Week Range$23.72▼$35.13VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.Read More… Receive PTHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Patheon N.V. Ordinary shares, p and its competitors with MarketBeat's FREE daily newsletter. Email Address PTHN Stock News HeadlinesLilium N.V - Ordinary Shares - Class ANovember 1, 2024 | money.usnews.comRobinhood Markets Inc - Ordinary Shares - Class AOctober 26, 2024 | money.usnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.June 9, 2025 | Weiss Ratings (Ad)NIO Inc. American depositary shares, each representing one Class A ordinary share (NIO) Pre-MarketOctober 23, 2024 | nasdaq.comImmatics NV Ordinary SharesOctober 16, 2024 | morningstar.comDimensional Fund Advisors Ltd. : Form 8.3 - BARRATT DEVELOPMENTS PLC - Ordinary SharesJuly 29, 2024 | lse.co.ukCTP NV Ordinary SharesMay 9, 2024 | morningstar.comLilium NV Ordinary Shares - Class A LILMMay 9, 2024 | morningstar.comSee More Headlines PTHN Stock Analysis - Frequently Asked Questions How were Patheon N.V. Ordinary shares, p's earnings last quarter? Patheon N.V. Ordinary shares, p (NYSE:PTHN) issued its quarterly earnings data on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. The company's quarterly revenue was up 3.2% compared to the same quarter last year. When did Patheon N.V. Ordinary shares, p IPO? Patheon N.V. Ordinary shares, p (PTHN) raised $625 million in an initial public offering on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers. What other stocks do shareholders of Patheon N.V. Ordinary shares, p own? Based on aggregate information from My MarketBeat watchlists, some other companies that Patheon N.V. Ordinary shares, p investors own include SVB Financial Group (SIVPQ), Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Alexion Pharmaceuticals (ALXN), NXP Semiconductors (NXPI), Bank of the Ozarks (OZRK) and Coherus BioSciences (CHRS). Company Calendar Last Earnings6/08/2017Today6/09/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:PTHN Previous SymbolNASDAQ:PTHN CIK1643848 Webwww.patheon.com Phone31-20-622-3243FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NYSE:PTHN) was last updated on 6/9/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Knows Exactly What He's DoingREVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Patheon N.V. Ordinary shares, p Please log in to your account or sign up in order to add this asset to your watchlist. Share Patheon N.V. Ordinary shares, p With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.